Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 436


Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study.

Gill H, Yim R, Lee HKK, Mak V, Lin SY, Kho B, Yip SF, Lau JSM, Li W, Ip HW, Hwang YY, Chan TSY, Tse E, Au WY, Kumana CR, Kwong YL.

Cancer. 2018 Jun 1;124(11):2316-2326. doi: 10.1002/cncr.31327. Epub 2018 Mar 26.


Subtype-specific incidence rates of lymphoid malignancies in Hong Kong compared to the United States, 2001-2010.

Bassig BA, Au WY, Mang O, Ngan R, Morton LM, Ip DK, Hu W, Zheng T, Seow WJ, Xu J, Lan Q, Rothman N.

Cancer Epidemiol. 2016 Jun;42:15-23. doi: 10.1016/j.canep.2016.02.007. Epub 2016 Mar 15.


Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.

Jaeger U, Trneny M, Melzer H, Praxmarer M, Nawarawong W, Ben Yehuda D, Goldstein D, Mihaljevic B, Ilhan O, Ballova V, Hedenus M, Hsiao LT, Au WY, Burgstaller S, Weidinger G, Keil F, Dittrich C, Skrabs C, Klingler A, Chott A, Fridrik MA, Greil R; AGMT-NHL13 Investigators.

Haematologica. 2015 Jul;100(7):955-63. doi: 10.3324/haematol.2015.125344. Epub 2015 Apr 24.


Genetic susceptibility to diffuse large B-cell lymphoma in a pooled study of three Eastern Asian populations.

Bassig BA, Cerhan JR, Au WY, Kim HN, Sangrajrang S, Hu W, Tse J, Berndt S, Zheng T, Zhang H, Pornsopone P, Lee JJ, Kim HJ, Skibola CF, Vijai J, Burdette L, Yeager M, Brennan P, Shin MH, Liang R, Chanock S, Lan Q, Rothman N.

Eur J Haematol. 2015 Nov;95(5):442-8. doi: 10.1111/ejh.12513. Epub 2015 Mar 13.


Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia.

Yang QM, Hong JY, Ko YH, Lin SY, Au WY, Choi MK, Park S, Kim SJ, Kim WS.

Onco Targets Ther. 2014 Sep 26;7:1717-22. doi: 10.2147/OTT.S67380. eCollection 2014.


Emergency internal carotid artery stenting with platelet glycoprotein IIbIIIa antagonist coverage in a patient with essential thrombocytosis.

Au WY, Law MF, Ma ES, Pang KH, Kan YT.

Ann Hematol. 2015 Mar;94(3):497-9. doi: 10.1007/s00277-014-2168-z. Epub 2014 Jul 24. No abstract available.


Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma.

Gill H, Au WY, Cheung WW, Lee EY, Kwong YL.

Ann Oncol. 2014 Jul;25(7):1391-7. doi: 10.1093/annonc/mdu142. Epub 2014 Apr 12.


Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.

Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, Greiner TC, Smith L, Guo S, Wilcox RA, Teh BT, Lim ST, Tan SY, Rimsza LM, Jaffe ES, Campo E, Martinez A, Delabie J, Braziel RM, Cook JR, Tubbs RR, Ott G, Geissinger E, Gaulard P, Piccaluga PP, Pileri SA, Au WY, Nakamura S, Seto M, Berger F, de Leval L, Connors JM, Armitage J, Vose J, Chan WC, Staudt LM; Lymphoma Leukemia Molecular Profiling Project and the International Peripheral T-cell Lymphoma Project.

Blood. 2014 May 8;123(19):2915-23. doi: 10.1182/blood-2013-11-536359. Epub 2014 Mar 14.


A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.

Ogura M, Ando K, Suzuki T, Ishizawa K, Oh SY, Itoh K, Yamamoto K, Au WY, Tien HF, Matsuno Y, Terauchi T, Yamamoto K, Mori M, Tanaka Y, Shimamoto T, Tobinai K, Kim WS.

Br J Haematol. 2014 Jun;165(6):768-76. doi: 10.1111/bjh.12819. Epub 2014 Mar 12.


Assessment of iron overload in very young children with limited thalassemia care resources in South China.

Au WY, Li CF, Fang JP, Chen GF, Sun X, Li CG, Zhang XH, Wu XD, Gao HY, Hao WG, Rasalkar D, Deng M, Mok SP, Tricta F, Chu WC.

Hemoglobin. 2014;38(2):119-26. doi: 10.3109/03630269.2014.880715. Epub 2014 Feb 7.


Sudden blindness due to bilateral central retinal artery occlusion in a patient on eltrombopag.

Au WY, Ma ES, Chow PC, Kan YT.

Ann Hematol. 2014 May;93(5):881-2. doi: 10.1007/s00277-013-1902-2. Epub 2013 Sep 19. No abstract available.


Thyroid arsenic content and papillary thyroid carcinoma arising 10 years after oral arsenic trioxide therapy for refractory acute promyelocytic leukemia.

Au WY, Lang BH, Fong BM, Mao KJ, Tam S.

Leuk Lymphoma. 2014 May;55(5):1184-5. doi: 10.3109/10428194.2013.837161. Epub 2013 Sep 23. No abstract available.


Preservation of lower incidence of chronic lymphocytic leukemia in Chinese residents in British Columbia: a 26-year survey from 1983 to 2008.

Mak V, Ip D, Mang O, Dalal C, Huang S, Gerrie A, Gillan T, Ramadan KM, Toze C, Au WY.

Leuk Lymphoma. 2014 Apr;55(4):824-7. doi: 10.3109/10428194.2013.827785. Epub 2013 Sep 12.


Effect of therapeutic arsenic exposure on pulmonary function.

Ho JC, Au WY, Han L, Kwong YL, Ip MS.

Respir Med. 2013 Sep;107(9):1423-30. doi: 10.1016/j.rmed.2013.06.012. Epub 2013 Jul 5.


International survey of T2* cardiovascular magnetic resonance in β-thalassemia major.

Carpenter JP, Roughton M, Pennell DJ; Myocardial Iron in Thalassemia (MINT) Investigators.

Haematologica. 2013 Sep;98(9):1368-74. doi: 10.3324/haematol.2013.083634. Epub 2013 Jun 28.


Regression of conjunctival maltoma with topical antibiotics and steroids.

Far NY, Au WY, Chow C, Choi PC, Chan KH, Young AL.

Ann Hematol. 2014 Feb;93(2):331-2. doi: 10.1007/s00277-013-1781-6. Epub 2013 May 9. No abstract available.


IL10 and TNF variants and risk of non-Hodgkin lymphoma among three Asian populations.

Hosgood HD 3rd, Au WY, Kim HN, Liu J, Hu W, Tse J, Song B, Wong KF, Lee JJ, Chanock SJ, Siu LP, Purdue MP, Shin MH, Yu J, Liang R, Kim HJ, Rothman N, Lan Q.

Int J Hematol. 2013 Jun;97(6):793-9. doi: 10.1007/s12185-013-1345-5. Epub 2013 May 3.


Asymptomatic bulky Hodgkin lymphoma over 8 years with elevated alpha fetoprotein.

Au WY, Wong SH, Suen WS, Ma ES, Chui WH.

Leuk Lymphoma. 2014 Jan;55(1):207-8. doi: 10.3109/10428194.2013.796047. Epub 2013 Jun 12. No abstract available.


MGUS prevalence in an ethnically Chinese population in Hong Kong.

Wu SP, Minter A, Costello R, Zingone A, Lee CK, Au WY, Landgren O.

Blood. 2013 Mar 21;121(12):2363-4. doi: 10.1182/blood-2012-11-466011. No abstract available.


JAK2 V617F mutation positive primary myelofibrosis with concomitant t(9;11;22)(q34;p15;q11.2) but no BCR/ABL fusion.

Au WY, Wan TS, Ma ES.

Int J Hematol. 2013 Mar;97(3):435-7. doi: 10.1007/s12185-013-1287-y. Epub 2013 Feb 7. No abstract available.


Supplemental Content

Loading ...
Support Center